Note the date: this August 19, the 105th anniversary of the death of the great Carlos Juan Finlay, Dr Vicente Vérez Bencomo, director of the prestigious national vaccine institute named after the distinguished scientist, presented to President Miguel Díaz Canel Bermúdez and the National Group of Experts to confront the pandemic, the first specific vaccine candidate against COVID-19 from the small and besieged Cuba.
“The vaccine has been arrived at with prudence, with measure, without showing off, taking the steps that had to be taken. That is why it was first registered properly and the first information will be given in depth by its protagonists”. The study has the fundamental authorization of the Center for State Control of the Quality of Medicines (CEDMED), which is the regulatory authority.
Soberana, the first Cuban vaccine candidate against COVID-19 in the FR (Front Runner) category, and identified by the initials FINLAY-FR-1, will enter the clinical trials phase as of Monday, August 24, that is, in human beings: 20 of at least one age group from 19 to 59 years old. A week later, the test will be applied to an equal number of volunteers between 60 and 80 years old. The second phase of these clinical trials is scheduled for September 11, when all 676 volunteers will be completed, including the 40 from the first phase.